Interstitial cell of Cajal autophagy pathway

The "Interstitial cell of Cajal autophagy pathway" is not a canonical therapeutic target such as a receptor, ion channel, or enzyme. Instead, it refers to the cellular process of autophagy as it occurs within **interstitial cells of Cajal (ICCs)**, which are specialized pacemaker cells in the gastrointestinal (GI) tract. ICCs generate the electrical slow waves regulating peristalsis and are integral for normal GI motility[3][7]. Autophagy in ICCs is increasingly recognized as important for maintaining their function and viability, especially under stress, injury, or disease conditions such as slow transit constipation, functional dyspepsia, and diabetic gastroparesis[1][3]. Dysregulation of autophagy in ICCs can lead to decreased cell numbers, impaired pacemaking, and GI motility disorders. Modulators of autophagy—whether physiological (e.g., electroacupuncture), pharmacological (e.g., certain herbal medicines), or genetic (e.g., miR-129-3p)—are being studied experimentally to preserve or restore ICC function and thus ameliorate GI motility disorders[1][5][3]. The pathway intersects with growth factor (e.g., stem cell factor/c-Kit), insulin/IGF-1, and neurotransmitter signaling, but it is not itself a druggable single molecule or receptor[4][1]. **Note:** - This is not a standard drug target or receptor, but rather a physiological process within a cell population; therefore, "is_target: false" and "is_incorrect: true" per your schema. - If seeking a canonical target, consider specifying "c-Kit receptor" or a downstream autophagy protein in ICCs. - Drugs acting on this pathway act indirectly by altering ICC autophagy and, consequently, GI motility[3][1].

Other names

Interstitial cells of Cajal autophagyICC autophagy pathwayICC autophagy

Modulation of PI3K/Akt/mTOR signaling pathway for autophagy regulation; Stimulation/inhibition of pacemaker activity in ICC affecting GI motility